Related Experiment Video
Updated: Jun 29, 2026
07:05
Ultrasound-guided Botulinum Toxin-A Injections: A Method of Treating Sialorrhea
Published on: November 9, 2016
Undesirable distant effects following botulinum toxin type a injection.
Nicolas Roche1, Alexis Schnitzler, François Genêt F
1Service de Physiologie d'Explorations Fonctionnelles, Faculty of Medicine Paris Ile-de-France Ouest, University of Versailles-Saint Quentin, Garches, France. roche.nicolas@rpc.aphp.fr
Clinical Neuropharmacology
|October 7, 2008
Summary
Clinical signs of botulinum toxin type A (BoNTA) spread from injection sites are rare but can be diagnosed using clinical, temporal, and electromyographic factors. Further research is needed to understand the mechanisms of BoNTA spread.
Area of Science:
- Neurology
- Pharmacology
- Clinical Electrophysiology
Background:
- Botulinum toxin type A (BoNTA) is widely used for treating spasticity.
- Understanding the potential spread of BoNTA from the injection site is crucial for patient safety and treatment efficacy.
Purpose of the Study:
- To determine the incidence of clinical signs associated with BoNTA spread.
- To investigate the diagnostic methods for identifying BoNTA spread.
Main Methods:
- Retrospective cohort study of patients receiving BoNTA for spasticity.
- Systematic assessment for adverse effects indicative of BoNTA spread.
- Clinical examination, single-fiber electromyography, and neuromuscular biopsy for suspected cases.
Main Results:
- Five out of 266 BoNTA injection sessions (187 patients) showed clinical signs of toxin spread.
- Single-fiber electromyography revealed increased jitter in four patients.
- Neuromuscular biopsy indicated recent denervation without reinnervation.
Conclusions:
- Diagnosis of BoNTA spread relies on clinical, temporal, and electromyographic findings.
- The clinical presentation of BoNTA spread is variable, and underlying mechanisms require further investigation.
- Prospective, randomized trials are necessary to elucidate BoNTA spread mechanisms and optimize treatment.
Related Concept Videos
01:22Botulism
Botulism is a life-threatening neuroparalytic condition caused by botulinum neurotoxin, which is produced by the bacterium Clostridium botulinum, a Gram-positive, spore-forming, obligate anaerobe.In adults, the toxin enters the body in different ways: in foodborne botulism, the preformed toxin is absorbed in the intestine. In wound botulism, spores grow in injured tissue and release the toxin into the blood. Infant botulism differs mechanistically from adult forms. In infants, botulism commonly...
01:21Skeletal Muscle Relaxants: Adverse Effects
Skeletal muscle relaxants are widely used for muscle paralysis and relieving pain following any muscle injury or stiffness. However, depending on the drug type, they can have adverse effects that range from mild to severe. Usually, nondepolarizing neuromuscular blockers have minimal side effects. For example, drugs like d-tubocurarine, cisatracurium, and rocuronium cause hypotension, whereas drugs like baclofen, when stopped abruptly, can lead to the recurrence of spastic conditions.
Unlike...
Unlike...
01:12Local Anesthetics: Adverse Effects
While local anesthetics are generally safe and well-tolerated, they can occasionally cause adverse effects that vary in severity. Local anesthetics can induce toxicity at two distinct levels. They can either produce local effects through direct contact with the neural elements or be absorbed into the bloodstream from the injection site, leading to systemic effects.
Once absorbed into the systemic circulation, local anesthetics can affect the organs that depend on the functioning of sodium...
Once absorbed into the systemic circulation, local anesthetics can affect the organs that depend on the functioning of sodium...
01:26Directly Acting Muscle Relaxants: Dantrolene and Botulinum Toxin
Directly acting muscle relaxants like dantrolene and botulinum toxin (BoNT) have distinct mechanisms and applications. Dantrolene, a hydantoin derivative, acts on the ryanodine receptor (RYR1) in skeletal muscle cells. RYR1 are calcium channels present at the sarcoplasmic reticulum membrane. In response to excitation, they release calcium ions from the sarcoplasmic reticulum to the cytosol. Calcium promotes actin-myosin-mediated contraction of muscles.
The binding of dantrolene to the RYR1...
The binding of dantrolene to the RYR1...
01:27Nondepolarizing (Competitive) Neuromuscular Blockers: Pharmacological Actions
Nondepolarizing neuromuscular blockers prevent the membrane depolarization of muscle cells and inhibit muscle contraction. These are usually administered with anesthetics to achieve complete muscle relaxation. Upon administration, these drugs first block the small, rapidly contracting muscles of the face and hands, followed by the larger muscles of the trunk and the intercostal muscles. The diaphragm is the last muscle to be affected.
Although all competitive neuromuscular blockers are designed...
Although all competitive neuromuscular blockers are designed...
01:19Depolarizing Blockers: Pharmocokinetics
Depolarizing blockers are administered through intravenous injection. Succinylcholine is the most common choice of depolarizing blockers in emergency clinical practices. Although they have a rapid onset, they readily diffuse away from the motor end plate into the extracellular fluid. They are metabolized by enzymes such as liver butyrylcholinesterase and plasma pseudocholinesterases. This produces a short duration of action, typically 5-10 minutes long, unlike nondepolarizing blockers, which...